146 related articles for article (PubMed ID: 37626449)
21. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Tsuboi M; Ohira T; Saji H; Miyajima K; Kajiwara N; Uchida O; Usuda J; Kato H
Ann Thorac Cardiovasc Surg; 2007 Apr; 13(2):73-7. PubMed ID: 17505412
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).
Kenmotsu H; Sugawara S; Watanabe Y; Saito H; Okada M; Chen-Yoshikawa TF; Ohe Y; Nishio W; Nakagawa S; Nagao H
Cancer Sci; 2022 Dec; 113(12):4327-4338. PubMed ID: 36062851
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Wakelee HA; Dahlberg SE; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Leighl NB; Aisner SC; Rothman JM; Patel JD; Sborov MD; McDermott SR; Perez-Soler R; Traynor AM; Butts C; Evans T; Shafqat A; Chapman AE; Kasbari SS; Horn L; Ramalingam SS; Schiller JH;
Lancet Oncol; 2017 Dec; 18(12):1610-1623. PubMed ID: 29129443
[TBL] [Abstract][Full Text] [Related]
24. Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Soh J; Okumura N; Nakata M; Nakamura H; Fukuda M; Kataoka M; Kajiwara S; Sano Y; Aoe M; Kataoka K; Hotta K; Matsuo K; Toyooka S; Date H
Jpn J Clin Oncol; 2016 Aug; 46(8):741-7. PubMed ID: 27207886
[TBL] [Abstract][Full Text] [Related]
25. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
Pisters KM; Evans WK; Azzoli CG; Kris MG; Smith CA; Desch CE; Somerfield MR; Brouwers MC; Darling G; Ellis PM; Gaspar LE; Pass HI; Spigel DR; Strawn JR; Ung YC; Shepherd FA; ;
J Clin Oncol; 2007 Dec; 25(34):5506-18. PubMed ID: 17954710
[TBL] [Abstract][Full Text] [Related]
26. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Custodio Carretero AB; García Sáenz JA; González Larriba JL; Bobokova J; Calles Blanco A; Hernando Trancho F; García Paredes B; Rodríguez Lajusticia L; Díaz-Rubio García E
Clin Transl Oncol; 2008 Sep; 10(9):560-71. PubMed ID: 18796373
[TBL] [Abstract][Full Text] [Related]
28. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).
Wada H; Miyahara R; Tanaka F; Hitomi S
Eur J Cardiothorac Surg; 1999 Apr; 15(4):438-43. PubMed ID: 10371118
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzáles-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P
Lancet Oncol; 2006 Sep; 7(9):719-27. PubMed ID: 16945766
[TBL] [Abstract][Full Text] [Related]
30. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
Schmid-Bindert G; Engel-Riedel W; Reck M; Schuette W; Stöhlmacher J; Fischer JR; Mazières J; Chouaid C; Wolf M; Vinolas N; Soldatenkova V; Ripoche V; Nguyen T; Visseren-Grul C
Lung Cancer; 2015 Dec; 90(3):397-404. PubMed ID: 26791798
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.
Malhotra J; Mhango G; Gomez JE; Smith C; Galsky MD; Strauss GM; Wisnivesky JP
Ann Oncol; 2015 Apr; 26(4):768-773. PubMed ID: 25600562
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan).
Eur J Surg Oncol; 1995 Feb; 21(1):69-77. PubMed ID: 7851558
[TBL] [Abstract][Full Text] [Related]
33. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
Arriagada R; Bergman B; Dunant A; Le Chevalier T; Pignon JP; Vansteenkiste J;
N Engl J Med; 2004 Jan; 350(4):351-60. PubMed ID: 14736927
[TBL] [Abstract][Full Text] [Related]
36. Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer.
Ganti AK; Williams CD; Gajra A; Kelley MJ
Cancer; 2015 Aug; 121(15):2578-85. PubMed ID: 25873330
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
39. Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan.
Yoh K; Takamochi K; Shukuya T; Hishida T; Tsuboi M; Sakurai H; Goto Y; Yoshida K; Ohde Y; Okumura S; Ohashi Y; Kunitoh H
Jpn J Clin Oncol; 2019 Jan; 49(1):63-68. PubMed ID: 30452719
[TBL] [Abstract][Full Text] [Related]
40. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
Johnson BE; Rabin MS
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
